In this study for quality assessment, next‐generation sequencing (NGS) was examined in a large cohort of NSCLC specimens to elucidate the incidence of IDH1/2 mutations and the clinicopathological and molecular characteristics of IDH1/2‐mutated NSCLCs. The gene discussed is IDH1; the disease is non-small cell lung carcinoma.